Project Grant R21AI190446
Award Date
7/17/25
Completion Date
6/30/27
Dollars Obligated
$481K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
This Project Grant award of $1,491,931 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research is focused on investigating the immune mechanisms by which GLP-1 receptor agonists can reduce inflammation in both lean and obese patients with asthma. The research aims to identify the cellular targets and anti-inflammatory pathways of GLP-1 signaling in order to inform the clinical repurposing of GLP-1R agonists for asthma...
This Project Grant award, totaling $744,977.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research at Emory University to explore the role of T cells in providing protection against respiratory virus transmission. Key objectives include defining the cellular interactions and molecular mechanisms of tissue-resident memory T cells (TRM) that can limit the spread of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $816,358 to Vanderbilt University Medical Center (VUMC) to conduct research on the effects of infant antibiotic exposure on the development of the early-life airway and gut microbiome, and the associated risk of childhood asthma. The goals of this 5-year project are to: 1) determine the age when infants are most susceptible to the harmful...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $740,709 to the University of Utah to conduct research on how early-life viral infections can lead to the development of childhood asthma. The key objectives are to define the cellular and molecular mechanisms by which viral-induced inflammation programs hyperactivated type 2 innate lymphoid cells (ILC2s) in the lung, and determine if these hyperactivated ILC2s...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $143,450 to support research on developing therapies for treating viral-induced acute lung injury. The primary focus is on evaluating the therapeutic efficacy of combinations of PPARG agonist and RXR ligand compounds in cotton rat models of influenza and respiratory syncytial virus (RSV) infection. The research...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $640,735.00 to Emory University to conduct research on understanding the mechanisms of CD8+ tissue-resident memory T cells (TRM) that mediate protection against respiratory virus transmission. The research aims to investigate the characteristics, durability, and molecular mechanisms of respiratory tract TRM...
This Project Grant award, valued at $185,866.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of airway epithelial syndecan-1 (SDC1) cleavage by leukocyte-derived heparanases in driving inflammation, barrier dysfunction, and steroid resistance in a preclinical model of severe, mixed-granulocytic allergic asthma. The research will evaluate the...
This Project Grant award of $565,834 from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (CFDA 93.837 Cardiovascular Diseases Research), aims to investigate the long-term impact of early-life respiratory syncytial virus (RSV) infection on the development of childhood asthma. The research will focus on understanding how RSV infection can cause epigenetic modifications in lung epithelial cells that lead to persistent changes in the lung's...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) totaling $364,484 aims to develop a novel bronchodilation strategy for severe respiratory syncytial virus (RSV) bronchiolitis in young children. The funded research will screen clinically relevant soluble guanylate cyclase (SGC) agonists for their bronchodilation efficacy and safety in RSV-infected pediatric airway models, and evaluate the therapeutic...
This $782,362 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of TREK-1 potassium channels in acute respiratory distress syndrome (ARDS). The key objectives are to: 1) determine if ARDS decreases epithelial and endothelial TREK-1 levels, leading to cell membrane depolarization and calcium-dependent inflammation, and 2) evaluate if activating residual TREK-1...